SENHWA BIOSCIENCES, INC.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
1. G-quadruplex (stabilizer)
2. Casein Kinase 2 (inhibitor)
2. Casein Kinase 2 (inhibitor)
The content above was translated by Ai
Founded Year
2012
Unified Business No.
54021973
Status
Active
Number of Employees
0
Total Paid-in
Capital
1,149,036,200 (NT$)
Location of Company
Taiwan
, New Taipei City
Exit Status
OTC listing(2017)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Senhwa Biosciences Inc. was established in 2012 and listed on the Taipei Exchange (TPEx) on April 24, 2017. The company aims to transform the model for new drug development by focusing on human efficacy. Senhwa believes that its dedication to science and rigorous processes will enable Senhwa to achieve remarkable milestones.
The content above was translated by Ai
